ProShare Advisors
DNTH icon

ProShare Advisors’s Dianthus Therapeutics DNTH Stock Holding History

ProShare Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Buy
6,194
+997
+19% +$87.1K ﹤0.01% 982
2026
Q1 		$436K Buy
+5,197
New +$301K ﹤0.01% 1146
2022
Q2 		– Sell
-731
Closed -$34K – 1881
2022
Q1 		$34K Sell
731
-195
-21% -$10.7K ﹤0.01% 2143
2021
Q4 		$67K Sell
926
-96
-9% -$9.65K ﹤0.01% 2248
2021
Q3 		$119K Sell
1,022
-117
-10% -$13.6K ﹤0.01% 1891
2021
Q2 		$178K Buy
1,139
+376
+49% +$69.1K ﹤0.01% 2176
2021
Q1 		$145K Buy
763
+10
+1% +$1.68K ﹤0.01% 2114
2020
Q4 		$94K Buy
753
+109
+17% +$12.4K ﹤0.01% 1997
2020
Q3 		$70K Buy
+644
New +$76.3K ﹤0.01% 1563
2020
Q1 		– Sell
-690
Closed -$167K – 1280
2019
Q4 		$167K Sell
690
-103
-13% -$19.2K ﹤0.01% 1630
2019
Q3 		$130K Sell
793
-5
-0.6% -$950 ﹤0.01% 1514
2019
Q2 		$188K Sell
798
-4
-0.5% -$989 ﹤0.01% 1452
2019
Q1 		$211K Buy
802
+74
+10% +$12.8K ﹤0.01% 1444
2018
Q4 		$66K Buy
+728
New +$99.2K ﹤0.01% 1513

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

ProShare Advisors's DNTH Position: Q2 2026 in Review

ProShare Advisors increased its Dianthus Therapeutics (DNTH) stake by 19% in Q2 2026, buying an estimated $87.1K and bringing the position to 6,194 shares worth $604K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

ProShare Advisors first reported a position in DNTH in Q4 2018 and has held it in 14 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • ProShare Advisors held 6,194 shares of Dianthus Therapeutics worth $604K as of Q2 2026.
  • ProShare Advisors bought 997 Dianthus Therapeutics shares in Q2 2026, an estimated $87.1K.
  • Dianthus Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #982 holding.
  • ProShare Advisors first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 14 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.